Malleability of the SARS-CoV-2 3CL Mpro Active-Site Cavity Facilitates Binding of Clinical Antivirals
Daniel W. Kneller, Stephanie Galanie, G.N. Phillips, Hugh O’Neill, Leighton Coates, Andrey Kovalevsky
Topics & Concepts
Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PandemicProteaseVirology2019-20 coronavirus outbreakBinding siteSars virusComputational biologyBiologyChemistryMedicineEnzymeBiochemistryInfectious disease (medical specialty)PathologyOutbreakDiseaseSARS-CoV-2 and COVID-19 ResearchInfluenza Virus Research StudiesViral Infections and Immunology Research